» Articles » PMID: 28329119

Stratification of Latent Mycobacterium Tuberculosis Infection by Cellular Immune Profiling

Overview
Journal J Infect Dis
Date 2017 Mar 23
PMID 28329119
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Recently acquired and remotely acquired latent Mycobacterium tuberculosis infection (LTBI) are clinically indistinguishable, yet recent acquisition of infection is the greatest risk factor for progression to tuberculosis in immunocompetent individuals. We aimed to evaluate the ability of cellular immune signatures that differ between active tuberculosis and LTBI to distinguish recently from remotely acquired LTBI.

Methods: Fifty-nine individuals were recruited: 20 had active tuberculosis, 19 had recently acquired LTBI, and 20 had remotely acquired LTBI. The proportion of mycobacteria-specific CD4+ T cells secreting tumor necrosis factor α (TNF-α) but not interferon γ or interleukin 2 which had a differentiated effector phenotype (TNF-α-only TEFF), and the level of CD27 expression on IFN-γ-producing CD4+ T cells, were detected by flow cytometry.

Results: The TNF-α-only TEFF signature was significantly higher in the group with recently acquired LTBI, compared with the group with remotely acquired LTBI (P < .0001), and it discriminated between these groups with high sensitivity and specificity, with an area under the curve of 0.87. Two signatures incorporating CD27 expression did not distinguish between recently and remotely acquired LTBI. Interestingly, the TNF-α-only TEFF signature in participants with recently acquired LTBI was more similar to that in participants with tuberculosis than that in participants with remotely acquired LTBI, suggesting that recently acquired LTBI is immunologically more similar to tuberculosis than remotely acquired LTBI.

Conclusions: These findings reveal marked biological heterogeneity underlying the clinically homogeneous phenotype of LTBI, providing a rationale for immunological risk stratification to improve targeting of LTBI treatment.

Citing Articles

Diagnostic accuracy of -specific triple-color FluoroSpot assay in differentiating tuberculosis infection status in febrile patients with suspected tuberculosis.

Zhang L, Li Y, Zou X, Ma H, Gao M, Ge Q Front Immunol. 2025; 15():1462222.

PMID: 39845975 PMC: 11751065. DOI: 10.3389/fimmu.2024.1462222.


Changes of Mycobacterium tuberculosis specific antigen-stimulated CD27CD38IFN-γCD4 T cells before and after anti-tuberculosis treatment.

Fang Y, Tang Y, Luo Q, Wang N, Tang L, Yang X Eur J Med Res. 2024; 29(1):147.

PMID: 38429734 PMC: 10908161. DOI: 10.1186/s40001-024-01713-x.


Know your tuberculosis epidemic-Is it time to add Mycobacterium tuberculosis immunoreactivity back into global surveillance?.

Rickman H, Kamchedzera W, Schwalb A, Phiri M, Ruhwald M, Shanaube K PLOS Glob Public Health. 2023; 2(10):e0001208.

PMID: 36962621 PMC: 10021854. DOI: 10.1371/journal.pgph.0001208.


Host Blood Transcriptional Signatures as Candidate Biomarkers for Predicting Progression to Active Tuberculosis.

Kim C, Choi G, Lee J Tuberc Respir Dis (Seoul). 2023; 86(2):94-101.

PMID: 36912017 PMC: 10073607. DOI: 10.4046/trd.2022.0152.


Study of CD27, CD38, HLA-DR and Ki-67 immune profiles for the characterization of active tuberculosis, latent infection and end of treatment.

Diaz-Fernandez S, Villar-Hernandez R, Stojanovic Z, Fernandez M, de Souza Galvao M, Tolosa G Front Microbiol. 2022; 13:885312.

PMID: 35935194 PMC: 9354672. DOI: 10.3389/fmicb.2022.885312.


References
1.
Berry M, Graham C, McNab F, Xu Z, Bloch S, Oni T . An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature. 2010; 466(7309):973-7. PMC: 3492754. DOI: 10.1038/nature09247. View

2.
Sutherland I . Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli. Adv Tuberc Res. 1976; 19:1-63. View

3.
Portevin D, Moukambi F, Clowes P, Bauer A, Chachage M, Ntinginya N . Assessment of the novel T-cell activation marker-tuberculosis assay for diagnosis of active tuberculosis in children: a prospective proof-of-concept study. Lancet Infect Dis. 2014; 14(10):931-8. DOI: 10.1016/S1473-3099(14)70884-9. View

4.
Wyndham-Thomas C, Corbiere V, Dirix V, Smits K, Domont F, Libin M . Key role of effector memory CD4+ T lymphocytes in a short-incubation heparin-binding hemagglutinin gamma interferon release assay for the detection of latent tuberculosis. Clin Vaccine Immunol. 2014; 21(3):321-8. PMC: 3957667. DOI: 10.1128/CVI.00651-13. View

5.
HART P, Sutherland I . BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Br Med J. 1977; 2(6082):293-5. PMC: 1630784. DOI: 10.1136/bmj.2.6082.293. View